LARGE SCALE “OMICS” STUDIES TO EXPLORE THE PHYSIOPATHOLOGY OF HIV-1 INFECTION
- 1Conservatoire National des Arts et Métiers (CNAM), France
- 2INSERM U1064 Centre de Recherche en Transplantation et Immunologie, France
- 3Institut de transplantation urologie-néphrologie (ITUN), France
- 4Ecole Centrale de Nantes, France
In this review, we present the main large-scale experimental studies that have been performed in the HIV/AIDS field. These ‘omics’ studies are based on several technologies including genotyping, RNA interference, transcriptome or epigenome analysis. Due to the direct connection with disease evolution, there has been a large focus on genotyping cohorts of well-characterized patients through genome-wide association studies (GWAS), but there have also been several in vitro studies targeting siRNA interference of HIV-1 infected cells or transcriptome analyses. After describing the major results obtained with these omics technologies -including some with a high relevance for HIV-1 treatment-, we discuss the next steps that the community needs to embrace in order to derive new actionable therapeutic or diagnostic targets. Only integrative approaches that combine all big data results and consider their complex interactions will allow to capture the global picture of HIV molecular pathogenesis. This novel challenge will require large collaborative efforts and represents a huge open field for innovative bioinformatics approaches.
Keywords: HIV - human immunodeficiency virus, AIDS - acquired immunodeficiency syndrome, GWAS - genome-wide association study, Genomics, big data, Omics and Big Data Analysis, trasncriptomics, siRNA - small interfering RNA, methylome analysis
Received: 30 Jan 2019;
Accepted: 30 Jul 2019.
Edited by:Dana C. Crawford, Case Western Reserve University, United States
Reviewed by:Paul J. McLaren, Public Health Agency of Canada (PHAC), Canada
Eric O. Johnson, RTI International, United States
Copyright: © 2019 Le Clerc, Limou and Zagury. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Sophie Limou, INSERM U1064 Centre de Recherche en Transplantation et Immunologie, Nantes, France, Sophie.Limou@univ-nantes.fr
Prof. Jean Francois Zagury, Conservatoire National des Arts et Métiers (CNAM), Paris, France, email@example.com